WO2007038754A3 - Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis - Google Patents

Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis Download PDF

Info

Publication number
WO2007038754A3
WO2007038754A3 PCT/US2006/038170 US2006038170W WO2007038754A3 WO 2007038754 A3 WO2007038754 A3 WO 2007038754A3 US 2006038170 W US2006038170 W US 2006038170W WO 2007038754 A3 WO2007038754 A3 WO 2007038754A3
Authority
WO
WIPO (PCT)
Prior art keywords
rheumatoid arthritis
treatment
gene expression
expression profiling
identification monitoring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/038170
Other languages
French (fr)
Other versions
WO2007038754A2 (en
Inventor
Danute Bankaitis-Davis
Kathy Storm
Lisa Siconolfi
David B Trollinger
Karl Wassmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SOURCE MDX
Original Assignee
SOURCE MDX
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SOURCE MDX filed Critical SOURCE MDX
Priority to AU2006294477A priority Critical patent/AU2006294477A1/en
Priority to EP06836158A priority patent/EP1945814A2/en
Priority to CA002624359A priority patent/CA2624359A1/en
Publication of WO2007038754A2 publication Critical patent/WO2007038754A2/en
Publication of WO2007038754A3 publication Critical patent/WO2007038754A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A method is provided in various embodiments for determining a profile data set for a subject with rheumatoid arthritis or inflammatory conditions related to rheumatoid arthritis based on a sample from the subject, wherein the sample provides a source of RNAs. The method includes using amplification for measuring the amount of RNA corresponding to at least 2 constituents from a gene panel. The profile data set comprises the measure of each constituent, and amplification is performed under measurement conditions that are substantially repeatable.
PCT/US2006/038170 2005-09-27 2006-09-27 Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis Ceased WO2007038754A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2006294477A AU2006294477A1 (en) 2005-09-27 2006-09-27 Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis
EP06836158A EP1945814A2 (en) 2005-09-27 2006-09-27 Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis
CA002624359A CA2624359A1 (en) 2005-09-27 2006-09-27 Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72105205P 2005-09-27 2005-09-27
US60/721,052 2005-09-27

Publications (2)

Publication Number Publication Date
WO2007038754A2 WO2007038754A2 (en) 2007-04-05
WO2007038754A3 true WO2007038754A3 (en) 2007-07-26

Family

ID=37708412

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/038170 Ceased WO2007038754A2 (en) 2005-09-27 2006-09-27 Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis

Country Status (5)

Country Link
US (1) US7935482B2 (en)
EP (2) EP2161348A1 (en)
AU (1) AU2006294477A1 (en)
CA (1) CA2624359A1 (en)
WO (1) WO2007038754A2 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1776471B9 (en) * 2004-05-25 2013-12-18 Hitachi Chemical Company, Ltd. Method of measuring cancer susceptibility
CN101044249B (en) * 2004-10-20 2012-09-05 日立化成工业株式会社 A method to customize drug delivery by quantifying mRNA
AU2005314089B2 (en) * 2004-12-08 2011-03-03 Cedars-Sinai Medical Center Methods for diagnosis and treatment of Crohn's disease
WO2010048415A1 (en) * 2008-10-22 2010-04-29 Cedars-Sinai Medical Center Methods of using jak3 genetic variants to diagnose and predict crohn's disease
KR100983450B1 (en) * 2005-04-28 2010-09-20 히다치 가세고교 가부시끼가이샤 In Vitro Gene Expression in Whole Blood as a Model for Evaluating Individual Diversity for Food Supplements
CN101194027B (en) 2005-06-08 2012-10-24 日立化成研究中心公司 Method for predicting immune response to neoplastic disease based on mRNA expression profiles in neoplastic cells and stimulated leukocytes
US7838239B2 (en) * 2006-04-07 2010-11-23 Hitachi Chemical Co., Ltd. Methods regarding enhanced T-cell receptor-mediated tumor necrosis factor superfamily mRNA expression in peripheral blood leukocytes in patients with crohn's disease
WO2007117589A2 (en) * 2006-04-07 2007-10-18 Hitachi Chemical Co., Ltd. Enhanced fc receptor-mediated tumor necrosis factor superfamily and chemokine mrna expression in peripheral blood leukocytes in patients with rheumatoid arthritis
US20100021917A1 (en) * 2007-02-14 2010-01-28 Cedars-Sinai Medical Center Methods of using genes and genetic variants to predict or diagnose inflammatory bowel disease
US20100190162A1 (en) * 2007-02-26 2010-07-29 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
WO2010039931A2 (en) * 2008-10-01 2010-04-08 Cedars-Sinai Medical Center Methods of using il17rd and il23-il17 pathway genes to diagnose crohn's disease
WO2008137762A2 (en) * 2007-05-04 2008-11-13 Cedars-Sinai Medical Center Methods of diagnosis and treatment of crohn's disease
US20100015156A1 (en) * 2007-03-06 2010-01-21 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel disease in children
US8486640B2 (en) 2007-03-21 2013-07-16 Cedars-Sinai Medical Center Ileal pouch-anal anastomosis (IPAA) factors in the treatment of inflammatory bowel disease
WO2008134569A2 (en) * 2007-04-26 2008-11-06 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease in the puerto rican population
CN101855367A (en) * 2007-11-14 2010-10-06 日立化成工业株式会社 FC receptor-mediated mRNA expression of tumor necrosis factor superfamily in peripheral blood leukocytes
EP2075343A1 (en) * 2007-12-21 2009-07-01 Gert Mayer A method of diagnosing a progressive disease
US20090215064A1 (en) * 2008-02-27 2009-08-27 Hitachi Chemical Co., Ltd. Quantitative assessment of individual cancer susceptibility by measuring dna damage-induced mrna in whole blood
WO2009155559A1 (en) * 2008-06-20 2009-12-23 Medimmune Llc Interferon alpha-induced pharmacodynamic markers
WO2010062960A2 (en) 2008-11-26 2010-06-03 Cedars-Sinai Medical Center METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
WO2010075579A2 (en) 2008-12-24 2010-07-01 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (mr-uc) requiring colectomy
WO2010142637A1 (en) * 2009-06-09 2010-12-16 Gert Mayer A method of diagnosing renal disorders
BR112012004777A2 (en) * 2009-09-03 2019-09-24 Genentech Inc Methods to Treat Diagnose and Monitor Rheumatoid Arthritis
EP3409289B1 (en) 2010-02-26 2020-09-30 Novo Nordisk A/S Stable antibody containing compositions
US9128101B2 (en) 2010-03-01 2015-09-08 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
CN102918165A (en) * 2010-03-24 2013-02-06 Tc园表达公司 Genes and genes combinations predictive of early response or non response of subjects suffering from inflammatory disease to cytokine targeting drugs (CYTD)
WO2011127219A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease
RU2012153786A (en) 2010-05-28 2014-07-10 Ново Нордиск А/С STABLE MULTI-DOSE COMPOSITIONS CONTAINING ANTIBODY AND CONSERVANT
KR20230109779A (en) 2013-03-27 2023-07-20 세다르스-신나이 메디칼 센터 Mitigation and reversal of fibrosis and inflammation by inhibition of tl1a function and related signaling pathways
EP4105236A1 (en) 2013-07-19 2022-12-21 Cedars-Sinai Medical Center Anti-tl1a (tnfsf15) antibody for treatment of inflammatory bowel disease
JP6624704B2 (en) 2015-08-31 2019-12-25 日立化成株式会社 Molecular methods for assessing urothelial disease
KR20180127416A (en) 2016-03-17 2018-11-28 세다르스-신나이 메디칼 센터 Diagnosis of Inflammatory Bowel Disease through RNASET2
US11480568B2 (en) * 2017-09-28 2022-10-25 Yeda Research And Development Co. Ltd. Diagnosis of autoimmune diseases
EP3765634A4 (en) 2018-03-16 2021-12-01 Scipher Medicine Corporation METHODS AND SYSTEMS FOR PREDICTING RESPONSE TO ANTI-TNF THERAPIES
GB2603294A (en) 2019-06-27 2022-08-03 Scipher Medicine Corp Developing classifiers for stratifying patients
CA3180476A1 (en) * 2020-05-29 2021-12-02 Robert B. Darnell Markers and cellular antecedents of rheumatoid arthritis flares
GB202009689D0 (en) * 2020-06-25 2020-08-12 Univ Ulster A method of predicting response to treatment with a disease-modifying anti-rheumatic drug and/or classifying disease activity in a subject with rheumatoid art
EP4437345A4 (en) * 2021-11-26 2026-01-14 Univ Rockefeller Markers and cellular benefits of luminescent tablets for rheumatoid arthritis
CN117717544A (en) * 2023-11-22 2024-03-19 中国人民解放军联勤保障部队第九二〇医院 Use of chrysin in the preparation of drugs for the treatment of rheumatoid arthritis
CN118186074A (en) * 2024-04-24 2024-06-14 华中科技大学同济医学院附属同济医院 Application of DPP4 as a marker and target for rheumatoid arthritis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003072827A1 (en) * 2001-10-31 2003-09-04 Children's Hospital Medical Center Method for diagnosis and treatment of rheumatoid arthritis
WO2004057034A1 (en) * 2002-12-19 2004-07-08 Source Precision Medicine, Inc. Identification, monitoring and treatment of infectious disease and characterization of inflammatory conditions related to infectious disease using gene expression profiles
WO2004110244A2 (en) * 2003-05-08 2004-12-23 Vanderbilt University A gene equation to diagnose rheumatoid arthritis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
WO1998024935A1 (en) 1996-12-06 1998-06-11 Urocor, Inc. Diagnosis of disease state using mrna profiles
ATE364721T1 (en) 1999-06-28 2007-07-15 Source Precision Medicine Inc METHOD FOR CHARACTERIZING BIOLOGICAL CONDITIONS USING CALIBRATED GENE EXPRESSION PROFILES
US20030224386A1 (en) 2001-12-19 2003-12-04 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of rheumatoid arthritis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003072827A1 (en) * 2001-10-31 2003-09-04 Children's Hospital Medical Center Method for diagnosis and treatment of rheumatoid arthritis
WO2004057034A1 (en) * 2002-12-19 2004-07-08 Source Precision Medicine, Inc. Identification, monitoring and treatment of infectious disease and characterization of inflammatory conditions related to infectious disease using gene expression profiles
WO2004110244A2 (en) * 2003-05-08 2004-12-23 Vanderbilt University A gene equation to diagnose rheumatoid arthritis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BOVIN LF ET AL.: "Blood cell gene expression profiling in rheumatoid arthritis - Discriminative genes and effect of rheumatoid factor", IMMUNOLOGY LETTERS, vol. 93, no. 2-3, 15 May 2004 (2004-05-15), pages 217 - 226, XP002419834 *

Also Published As

Publication number Publication date
US20070196835A1 (en) 2007-08-23
EP2161348A1 (en) 2010-03-10
US7935482B2 (en) 2011-05-03
WO2007038754A2 (en) 2007-04-05
CA2624359A1 (en) 2007-04-05
EP1945814A2 (en) 2008-07-23
AU2006294477A1 (en) 2007-04-05

Similar Documents

Publication Publication Date Title
WO2008063414A3 (en) Gene expression profiling for identification, monitoring, and treatment of colorectal cancer
WO2008063413A3 (en) Gene expression profiling for identification, monitoring, and treatment of lung cancer
WO2008123866A3 (en) Gene expression profiling for identification, monitoring and treatment of ovarian cancer
WO2008069881A3 (en) Gene expression profiling for identification, monitoring and treatment of melanoma
WO2008121132A3 (en) Gene expression profiling for identification, monitoring, and treatment of prostate cancer
WO2008143639A3 (en) Gene expression profiling for identification, monitoring, and treatment of cervical cancer
WO2010006048A3 (en) Gene expression profiling for predicting the survivability of prostate cancer subjects
WO2010080702A3 (en) Gene expression profiling for the identification, monitoring, and treatment of prostate cancer
WO2004099432A3 (en) Identification of biomarkers for detecting pancreatic cancer
DE602006003615D1 (en) Glucose biosensor and method
MX2010000971A (en) System and methods for determination of analyte concentration using time resolved amperometry.
EP2073691A4 (en) METHOD AND SYSTEM FOR DYNAMICALLY UPDATING CALIBRATION PARAMETERS OF A DETECTOR OF SUBSTANCES TO BE ANALYZED
DE60020119D1 (en) Method and device for investigating drug candidates and for determining their pharmacokinetic parameters
WO2009104016A3 (en) Methods of calibrating a sensor in a patient monitoring system
WO2006099151A3 (en) System and methods for processing analyte sensor data for sensor calibration
WO2004013609A3 (en) Use of biomarkers for detecting ovarian cancer
WO2007061992A3 (en) Method and apparatus for background current arrangements for a biosensor
WO2007025044A8 (en) Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
ATE504044T1 (en) PARAMETRIC CALIBRATION PROCEDURE
ES2349107T8 (en) ANALYTICAL AND INSTRUMENT METHOD.
WO2010053800A3 (en) Method and apparatus for visual field monitoring
ATE408829T1 (en) METHODS AND ASSAY KITS FOR DETECTING MONONUCLEAR CELL PHENOTYPES
WO2007141023A3 (en) Method of determining enzymatic activity in biological media
WO2005094332A3 (en) Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators in non-small cell lung cancer
WO2008091708A3 (en) Gene expression profiling for identification, monitoring, and treatment of lupus erythematosus

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2624359

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006294477

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2006294477

Country of ref document: AU

Date of ref document: 20060927

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2006836158

Country of ref document: EP